{"schema_version":"secwatch.filing_event.v1","accession":"0001802768-23-000013","form_type":"8-K","ticker":"RPRX","cik":"0001802768","company_name":"Royalty Pharma plc","filed_at":"2023-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.668406+00:00","generated_at":"2026-06-15T09:45:13.847610+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Royalty Pharma Q1 adjusted cash receipts $1,131M (+87% YoY); reaffirms FY guidance $2,850-2,950M","bullets":["Adjusted Cash Receipts $1,131M, +87% YoY; underlying growth 11% ex-Zavzpret milestone and Biohaven payments.","GAAP net cash from ops $1,034M (+125% YoY) includes $475M Zavzpret milestone and $35M Airsupra payment.","Announced up to $1.6B in new royalty deals (Spinraza, pelacarsen, KarXT) and $1.0B share buyback program.","Reaffirmed FY23 Adjusted Cash Receipts guidance $2,850-2,950M (underlying growth 4-9% ex-milestones).","Portfolio milestones: FDA approvals for Zavzpret, Airsupra, Trodelvy; positive Xtandi Phase 3 data."],"urls":{"canonical":"https://secwatch.observer/filing/0001802768-23-000013","json":"https://secwatch.observer/filing/0001802768-23-000013.json","markdown":"https://secwatch.observer/filing/0001802768-23-000013.md","text":"https://secwatch.observer/filing/0001802768-23-000013.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1802768/000180276823000013/0001802768-23-000013-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1802768/000180276823000013/rprx-20230509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T09:45:13.847610+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4ed40a552418bc05f87261fb31ff00715a128e1e","claim":"Royalty Pharma plc updated its the quarter ended March 31, 2023 guidance (reaffirmed).","evidence_excerpt":"On May 9, 2023, Royalty Pharma plc issued a press release announcing its financial results for the quarter ended March 31, 2023. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1802768/000180276823000013/0001802768-23-000013-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2023"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}